Luseogliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, may offer renal benefits in patients with type 2 diabetes mellitus and advanced chronic kidney disease (CKD), according to a study published in the Journal of Diabetes Investigation.

In this multicenter, randomized, open-label trial, 152 patients with type 2 diabetes and an estimatedglomerular filtration rate (eGFRcreat) between 15 and 45 mL/min/1.73 m² were assigned to receive luseogliflozin or standard care. The primary endpoint, change in eGFRcreat over 104 weeks, did not differ significantly between groups. Luseogliflozin produced an early decline in eGFR from weeks 2 to 12, with the greatest drop at week 4, followed by stabilization. The chronic eGFR slope was less negative in the luseogliflozin group, although not statistically significant.

Subgroup analyses revealed greater renal benefit in patients with baseline eGFR < 30 mL/min/1.73 m², urinary albumin/creatinine ratio < 30 mg/g, systolic blood pressure < 130 mmHg, or female sex. These results suggest that while the overall effect was modest, luseogliflozin may help slow kidney function decline after the early dip, offering potential renoprotective benefit in select high-risk populations with type 2 diabetes and CKD